New commitment to net-zero science-based targets confirms Clario’s industry-leading sustainability strategy

Commitment to science-based greenhouse gas emissions reduction targets accelerates Clario’s environmental sustainability plan.

• Science-based targets provide a clearly defined pathway for companies to reduce greenhouse gas emissions.
• Clario’s net-zero target and commitment to the Science Based Targets initiative (SBTi), demonstrates an industry-leading commitment to climate action.
• Chief Diversity, Inclusion and Sustainability Officer, Otis Johnson, reaffirms Clario’s commitment to ambitious environmental, social and governance (ESG) targets.

PHILADELPHIA, PA – July 13, 2022 – Clario, a technology company that delivers the leading endpoint solutions for decentralized (DCT), hybrid and site-based clinical trials, today announced it has committed to the Science Based Targets initiative with a net-zero ambition. Clario’s commitment to set energy and emissions reduction targets grounded in science is a step toward its goal of achieving net-zero by 2045.

The SBTi is a partnership between the Carbon Disclosure Program (CDP), the United Nations (UN) Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF) that establishes and promotes best practices for organizations in a science-based target setting. Science-based targets provide a clearly defined pathway for companies to reduce greenhouse gas emissions, helping prevent the worst impacts of climate change and future-proof business growth.

“We are stewards of equitable health outcomes and see a strong link between the health of thepatients we serve and the health of our planet. Our public environmental commitments and strong actions to become carbon neutral demonstrate that we have raised our ambitions and lifted our game,” said Otis Johnson, Ph.D., M.P.A., Clario’s Chief Diversity, Inclusion and Sustainability Officer. “We believe that we must actually reduce the emissions from where we are – inside our own walls and throughout our supply chain.”

“Astorg is extremely proud of Clario’s climate commitment and congratulates the company’sma nagement team for its leadership and engagement on sustainability,” said Judith Charpentier, Clario board member and partner at Astorg. “As one of the first private equity firms in the world to have a Science-Based Target for its portfolio, Astorg has been working closely with Clario to measure its greenhouse gas emissions and to support the company’s Sustainability ambitions.”

The SBTi drives climate action by helping the private sector set science-based emission reduction targets. Clario’s commitment will be recognized by the We Mean Business coalition and the UN Global Compact and will be entered into the Business Ambition for 1.5°C and Race to Zero campaigns. Earlier this year, Clario endorsed the UN Global Compact, pledging to advance societal goals by aligning its strategy and operations with the UN Ten Principles on human rights, labor, environment and anti-corruption.

For more information on Clario’s commitment to sustainable business practices, read our ESG
report here.

About Clario

Clario is a leading technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario’s solutions have been powering hybrid and decentralized clinical trials (DCT) for over 15 years, enabling sponsors to collect high quality endpoint data from any modality or location, all while improving the patient experience and diversity. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. With 30 facilities in nine countries, Clario’s global team of science, technology and operational experts has helped deliver over 19,000 trials and 870 regulatory approvals for over 5 million patients in 120 countries. Our innovation has been transforming clinical trials for 50 years.

Clario Media Contact

Duncan Cantor
Sr. Director, Corporate Communications
[email protected]